Intellia Therapeutics is hoping to transform the future of medicine with its gene-editing technology. » Read More
Lost in the coverage of the Pfizer-Wyeth deal that day, but nonetheless disclosed in the company's simultaneous earnings release back on January 26th of this year, PFE revealed it had taken a $2.3 billion charge for a pending settlement over marketing.
Virtually every large pharmaceutical company seems to have discovered cancer, and a substantial portion of the smaller biotechnology companies are focused on it as well. Together, the companies are pouring billions of dollars into developing cancer drugs.
Boston Scientific has rallied back to its highest levels since last year's financial crisis and is scheduled to discuss a key defibrillator trial this morning, prompting one large investor to position for a potential decline.
After a long delay, Eli Lilly finally launched its new bloodthinner Effient just this month. But analysts are already buzzing about what's next.
Are there any buying opportunities for investors on the horizon? Jeffrey Saut at Raymond James and Douglas Cliggott at Dover Management shared their market oulooks.
British drugmaker GlaxoSmithKline is trying to keep from having to tighten its belt over new safety concerns with its weightloss pill, alli
Am I missing something? Or is this not the way to go about advancing your cause?
The rally on Wall Street fizzled Monday, snapping a four-day streak that sent stocks up more than 4 percent. The Dow ended pretty much flat, while the Nasdaq and S&P 500 shed 0.1 percent.
Stocks opened higher Monday, extending their recent winning streak, with world shares hitting 10-month highs on hopes that the global economic recovery is picking up steam.
Stock index futures pointed to yet another positive open for Wall Street Monday, with world shares hitting 10-month highs on hopes that the global economic recovery is picking up steam.
Not having a public option in the Obama healthcare reform bill is good for the the larger managed care group, says health care analyst Thomas Carroll of Stifel Nicoluas.
A growing body of evidence suggests that doctors at some of the nation’s top medical schools have been attaching their names and lending their reputations to scientific papers that were drafted by ghostwriters working for drug companies - articles that were carefully calibrated to help the manufacturers sell more products.
It sounds like a simple idea for improving health care: draw up guidelines on how best to treat a particular illness and then pay doctors to follow them. That strategy, which some insurers and health plans already employ, has been embraced during the health care debate by some lawmakers in Congress who want to extend it more broadly.
Dan Deighan, founder of Deighan Financial Advisors, and Rob Stein, managing partner at Astor Asset Management, explained their positions on the economy and shared their market outlooks.
Before I go on vacation for a week I wanted to close the loop and offer some random thoughts on a few things.
Amid the ongoing healthcare reform brouhaha, pharma stocks are getting buffeted.
OK. I have to put aside the fact that he went to Notre Dame and is a diehard Fighting Irish fan (Go 'SC!), but Regis' trademark rant against Pfizer on "Fast Money" yesterday is too good not to blog it.
For years the Dendreon saga was centered around the controversy over whether its prostate cancer treatment worked or not. Well, now that we know the answer to that question the focus has turned to potential FDA approval of the therapeutic vaccine and the company's ability to make it and master the unique treatment process.
I know it's trite and cliche, but I learn something new almost every day on this beat. Take pseudobulbar affect. I'd never heard of it before. I had to Google it when I got a press release late yesterday announcing that Avanir Pharmaceuticals was going to unveil late-stage test results on a drug for it this morning.
Plus, Cramer comments on managing risk, dividend-paying stocks and more.